Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S42-S47

  Ray Coquard, Isabelle ^a   Brown, Jubilee ^b   Harter, Philipp ^c   Provencher, Diane M ^d   Fong, Peter C ^e   Maenpaa, Johanna ^f   Ledermann, Jonathan A ^g   Emons, Gunter ^h   Rigaud, Dominique Berton ⁱ   Glasspool, Rosalind M ^j   Mezzanzanica, Delia ^k   Colombo, Nicoletta ^l  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c KLINIKEN ESSEN MITTE   (Germany)

^d NOTRE DAME HOSPITAL   (Canada)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ UMR INSERM U892 CNRS 6299   (France)

^j BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^k NATIONAL CANCER INSTITUTE   (Italy)

^l UNIVERSITY OF MILANO BICOCCA   (Italy)

more..

Author keywords

First line treatment; Metastatic disease; Molecular analysis; Rare tumor; Sex cord stromal tumors

Indexed keywords

PLATINUM;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; MOLECULAR BIOLOGY; OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SEX CORD TUMOR; ADULT; CONSENSUS; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; SEX CORD-GONADAL STROMAL TUMORS;

ADULT; COMBINED MODALITY THERAPY; CONSENSUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SEX CORD-GONADAL STROMAL TUMORS; SOCIETIES, MEDICAL;

EID: 84988719181     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000249     Document Type: Review

References (35)

1. Gatta G, van der Zwan JM, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47:2493-2511.
2. Zaloudek C, Norris HJ. Sertoli-Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol. 1984;8:405-418.
3. Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary - an analysis of 376 women. Gynecol Oncol. 2007;104:396-400.
4. Garcia AA, Morrow CP. Stromal tumors of the ovary. In: Raghavan D, Brecher M, Johnson DH, et al, eds. Textbook of Uncommon Cancer. 2nd ed. John Wiley & Sons; 1999; 661-669.
5. Ray-Coquard I, Cassier P, Treilleux I, et al. Ovarian rare tumors. Impact of a French-speaking website on medical practice and inclusions in a clinical trial. Results after 1 year. Eur J Cancer. 2004.
6. Long W, Wang W, Rey R. Study on the anti-mullerian hormone served as a marker for granulosa cell tumor of ovary [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2000;35:356-358.
7. Lane AH, Lee MM, Fuller AF Jr., et al. Diagnostic utility of mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol. 1999;73:51-55.
8. Chu S, Rushdi S, Zumpe ET, et al. FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod. 2002;8:426-433.
9. Fuller PJ, Chu S. Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab. 2004;15:122-128.
10. Al-Agha OM, Huwait HF, Chow C, et al. FOXL2 is a sensitive and specific marker for sex cord - stromal tumors of the ovary. Am J Surg Pathol. 2011;35:484-494.
11. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719-2729.
12. D'Angelo E, Mozos A, Nakayama D, et al. Prognostic significance of FOXL2 mutation and mRNA expression in adult and juvenile granulosa cell tumors of the ovary. Mod Pathol. 2011;24:1360-1367.
13. Schultz KA, Pacheco MC, Yang J, et al. Ovarian sex cord - stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol. 2011;122:246-250.
14. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med. 2012;366:234-242.
15. Gershenson DM. Current advances in the management of malignant germ cell and sex cord - stromal tumors of the ovary. Gynecol Oncol. 2012;125:515-517.
16. Connolly DC, Katabuchi H, Cliby WA, et al. Somatic mutations in the STK11/LKB1 gene are uncommon in rare gynecological tumor types associated with Peutz-Jegher's syndrome. Am J Pathol. 2000;156:339-345.
17. Colombo N, Peiretti M, Garbi A, et al. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl 7):vii20-vii26.
18. Pankratz E, Boyes DA, White GW, et al. Granulosa cell tumors. A clinical review of 61 cases. Obstet Gynecol. 1978;52:718-723.
19. Thrall MM, Paley P, et al. Patterns of spread and recurrence of sex cord - stromal tumors of the ovary. Gynecol Oncol. 2011;122:242-245.
20. Bu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol. 2006;103:31-34.
21. Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol. 2009;113:86-90.
22. Evans AT, Gaffey TA, Malkasian GDJ, et al. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol. 1980;55:231-238.
23. Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol. 2003;21:2357-2363.
24. Pautier P, Gutierrez-Bonnaire M, Rey A, et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer. 2008;18:446-452.
25. Burger HG, Fuller PJ, Chu S, et al. The inhibins and ovarian cancer. Mol Cell Endocrinol. 2001;180:145-148.
26. Mangili G, Sigismondi C, Frigerio L, et al. Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol. 2013;130:38-42.
27. Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol. 2004;22:3517-3523.
28. Cecchetto G, Ferrari A, Bernini G, et al. Sex cord stromal tumors of the ovary in children: a clinicopathological report from the Italian TREP project. Pediatr Blood Cancer. 2011;56:1062-1067.
29. Colombo N, Parma G, Zanagnolo V, et al. Management of ovarian stromal cell tumors. J Clin Oncol. 2007;25:2944-2951.
30. Hardy RD, Bell JG, Nicely CJ, et al. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol. 2005;96:865-869.
31. Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol. 2009;114:431-436.
32. Brown J, Brady WE, Schink J, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014;120:344-351.
33. Rubin EH, Agrawal NG, Friedman EJ, et al. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res. 2006;12:7039-7045.
34. Cassier PA, Lefranc A, Amela EY, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013;109:909-914.
35. Leibl S, Bodo K, Gogg-Kammerer M, et al. Ovariangranulosacell tumors frequently express EGFR (Her-1), Her-3, and Her-4: an immunohistochemical study. Gynecol Oncol. 2006;101:18-23.